Cancer discovery news
Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.
Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Faulty molecule offers new target for treating liver cancer
Blocking a single faulty molecule in a biological process that drives the growth of advanced liver cancers could offer a new way to treat the disease, researchers have found.
2D building blocks can build better 3D drugs
Creating cancer drugs that better resemble 3D structures in cells is all about how you put the building blocks together, a new study has shown.
Quarter-of-a-million-pound ICR fundraiser needs your vote for JustGiving Awards
Bowel cancer patient and fundraiser Tim Morgan has been nominated for JustGiving’s Fundraising Team of the Year award after raising more than £250,000 for the ICR — and he needs your vote!
-content.tmb-hbmobile.jpg?Culture=en&sfvrsn=fec93f9d_2 "Dispensing medicines for a clinical trial (Jan Chlebik for the ICR, 2014) content")
‘Game-changing’ immunotherapy doubles head and neck cancer survival
An immunotherapy drug has been hailed as a potential ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer — a disease which is notoriously difficult to treat.
ICR Chief Executive Professor Paul Workman receives award from Spanish Cancer Foundation
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, has been given a special award for his services to cancer research by the charity Cancer Research Innovation Spain (CRIS) at its annual gala ball.
Professor Stan Kaye awarded Cancer Research UK lifetime achievement prize
Professor Stan Kaye, one of The Institute of Cancer Research, London’s most eminent researchers, has been awarded the Lifetime Achievement in Cancer Research Prize by Cancer Research UK.
‘Self-assembling’ molecules help key signalling pathway in bowel cancer
A key protein in cancer ‘self-assembles’ into structures which help drive signalling processes that fuel bowel cancer growth, a new study shows.
New treatment approach may offer hope to patients with aggressive childhood cancers
Targeted treatments that attack cancer metabolism could treat some of the most aggressive childhood cancers caused by faulty activation of a gene called MYCN, new research outlines.
3D-printed ‘AbdoMan’ could transform radiotherapy
A 3D-printed human torso is helping doctors safely and reliably model ‘internal radiation’ treatments for cancer.
Statement about NICE decision on T-VEC for treating inoperable metastatic melanoma
The Institute of Cancer Research, London, has issued the following statement from Professor Kevin Harrington in response to the decision by NICE to approve the use of talimogene laherparepvec (T-VEC) for treating inoperable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.
Men with high genetic chance of bowel cancer could have lower risk with healthy lifestyles
Men with a high genetic risk of developing bowel cancer over the next 25 years could have a lower risk of developing the disease if they also have a healthy lifestyle, according to a study.
ProNAi licenses oncology drug targeting DNA damage response Checkpoint kinase 1 (Chk1) from CRT Pioneer Fund, UK
ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced that it has obtained an exclusive license from the CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737 (formerly CCT245737), a highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1 (Chk1).